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Abstract
During the past decade, progress in endocrine therapy and the use of trastuzumab has significantly
contributed to the decline in breast cancer mortality for hormone receptor-positive and ERBB2
(HER2)-positive cases, respectively. As a result of these advances, a breast cancer cluster with poor
prognosis that is negative for the estrogen receptor (ESR1), the progesterone receptor (PRGR)
and ERBB2 (triple negative) has come to the forefront of medical therapeutic attention. DNA
microarray analyses have revealed that this cluster is phenotypically most like the basal-like breast
cancer that is caused by deficiencies in the BRCA1 pathways. To gain further improvements in
breast cancer survival, new types of drugs might be required, and small molecules targeting the
ubiquitin proteasome system have moved into the spotlight. The success of bortezomib in the
treatment of multiple myeloma has sent encouraging signals that proteasome inhibitors could be
used to treat other types of cancers. In addition, ubiquitin E3s involved in ESR1, ERBB2 or BRCA1
pathways could be ideal targets for therapeutic intervention. This review summarizes the ubiquitin
proteasome pathways related to these proteins and discusses the possibility of new drugs for the
treatment of breast cancers.
Publication history: Republished from Current BioData's Targeted Proteins database (TPdb;
http://www.targetedproteinsdb.com).
Protein pathway involvement in disease
The UPS in breast cancer
The ubiquitin proteasome system (UPS) consists of sev-
eral crucial enzymes: a ubiquitin-activating enzyme (E1),
a ubiquitin-conjugating enzyme (E2), a ubiquitin ligase
(E3) and the 26S proteasome [1,2]. The E3 catalyzes the
formation of polyubiquitin chains (and sometimes
monoubiquitylation), utilizing ubiquitin monomers that
have been activated by the E1 and E2 enzymes, and trans-
fers them onto a specific substrate(s). Depending upon
the type of ubiquitin chain, the ubiquitin modifications
signal a variety of processes, including 26S proteasome-
dependent degradation [3-5]. By contrast, ubiquitin mod-
ifications are negatively controlled by deubiquitylation
enzymes (DUBs) [6].
Remarkably, there are ~1000 E3s, categorized into sub-
families based on the structure of their catalytic site,
including 300–500 Cullin-ROC/Rbx complexes, ~450
RING-type proteins, ~40 HECT-type proteins and ~20 U-
box-type proteins. When comparing this with the ~500
mammalian protein kinases, it is easy to appreciate that
the UPS contributes to most, if not all, cellular events.
Therefore, it is realistic to anticipate major drug discover-
ies from this field, just like there have been in the kinase
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recently with proteasome inhibitors.
Estrogen receptors and the UPS
The α subunit of the estrogen receptor (ESR1) is degraded
by the UPS, and compounds inhibiting its degradation
could accelerate breast cancer growth [7]. However, the
mechanism underlying its proteolysis might not be
straightforward as there are at least two pathways for deg-
radation: ligand-independent and ligand-dependent. For
ligand-independent degradation, unliganded ESR1 asso-
ciates with a protein complex containing Hsc/Hsp70 (a
protein chaperone) and STUB1 (CHIP), an E3 ligase con-
taining a U-box. STUB1 preferentially recognizes mis-
folded ESR1 and targets this protein for ubiquitin-
mediated proteolysis. This pathway is important for the
quality control of ESR1 [8,9]. Inhibition of this pathway
could increase the active ESR1 pool. Alternatively, a dom-
inant-negative effect could be induced by accumulation of
misfolded ESR1.
Ligand-dependent degradation of ESR1 is mediated by
different E3 ligases and is required for estrogen-induced
transactivation. In HeLa cells expressing ESR1, treatment
with MG132, a proteasome inhibitor, resulted in ESR1
stabilization but impaired ESR1-mediated transcription
[10]. Cyclical recruitment of E3 ligases to ESR1 and bind-
ing of ESR1 to the proteasome is necessary for transcrip-
tional activation of estrogen-responsive promoters
[11,12]. During this process, the proteasome plays a cen-
tral role in the clearance of ESR1-regulated transcription
complexes, and inhibition of proteasomal activity pre-
vents cycling of ESR1 onto promoters. Putative proteins
involved in this process include: i) E3 ligases UBE3A
(E6AP) [13,14], MDM2 [15] and TRI25 (EFP) [16]; ii) the
20S catalytic proteasome subunit beta type-9 (PSB9; also
known as LMP2) [12] and the 26S protease regulatory
subunit 8 (PRS8; also known as Rpt6/TRIP1/SUG1),
which is a subunit of the 19S regulatory cap of the protea-
some [11]; and iii) NCOA1 (SRC), which interacts directly
with PSB9 [12] and NCOA3 (AIB1), which interacts with
UBE3A [17]. UBE3A and TRI25 are preferentially recruited
to estrogen-liganded ESR1, whereas MDM2 preferentially,
but not exclusively, associates with unliganded ESR1
[11,16]. NCOA3 is the p160 ESR1 transcriptional coacti-
vator and is amplified or overexpressed in breast cancer.
An Ncoa3 transgenic mouse shows a high incidence of
tumors in multiple organs, including breast [18,19].
ERBB2, EGFR and UPS
ERBB2 (HER2) and EGFR (ERBB1, HER1) are growth fac-
tor receptors (GFRs), members of the transmembrane
receptor tyrosine kinase family, and are overexpressed in
25–30% and 7–20% of breast cancers, respectively [20-
22]. Similar to ESR1 ligand-dependent and -independent
degradation, ubiquitylation is involved in the downregu-
lation of GFRs. Ligand-dependent dimerization of EGFR
increases tyrosine kinase activity and autophosphoryla-
tion of cytoplasmic tyrosine residues [23], and this ena-
bles interaction with the RING-domain-containing E3
ubiquitin-protein ligase CBL (c-CBL) in addition to
downstream effectors SHC1 (SHC) and GRB2. CBL is
phosphorylated by EGFR, which increases its ubiquitin
ligase activity towards EGFR [24]. EGFR is then translo-
cated to the endosomal compartment by SH3K1 (CIN85)
and endophilins [25] and subsequently sorted for either
recycling to the plasma membrane or destruction [26,27].
By contrast, phosphorylated ERBB2 only weakly associ-
ates with CBL and is resistant to CBL-induced downregu-
lation [28]. In addition, ERBB2-EGFR heterodimerization
blocks CBL association with EGFR and inhibits its lyso-
somal degradation, resulting in enhanced signaling [28-
31]. Interestingly, antibody-induced ERBB2 tyrosine
phosphorylation at Tyr1112 mediates interaction of the
receptor with CBL, leading to receptor ubiquitylation and
degradation [32]. By contrast, ligand-independent degra-
dation of ERBB2 is mediated by STUB1 in collaboration
with heatshock proteins Hsp70 and Hsp90 [33-36].
BRCA1 and basal-like cancer
Gene-expression profiling identified basal-like breast can-
cer as an exceptional cluster with poor prognosis and a
unique chemosensitivity. These cancers express basal/
myoepithelial cell markers such as cytokeratins 5/6, 14
and 17 or vimentin [37-39] but do not express ESR1, pro-
gesterone receptor (PRGR) or ERBB2 (triple negative)
[37]. Approximately 15% of sporadic breast cancers are
characterized by this phenotype [37], but this particular
cluster additionally possesses the dominant characteristics
of aggressive breast cancers that are insensitive to both
hormone therapy and trastuzumab (Herceptin, Genen-
tech) [38], a humanized monoclonal antibody directed
against ERBB2. Therefore, treatments that specifically tar-
get this subset of breast cancers could dramatically
improve the overall prognosis for breast cancers. Interest-
ingly, 80–90% of hereditary breast cancers with muta-
tions in the gene encoding BRCA1 display a basal-like
phenotype, suggesting that a deficiency in the BRCA1
pathway might cause this specific phenotype [39-43].
Indeed, BRCA1 dysfunction in sporadic basal-like cancers
has been reported [44-46], and conditional deletion of
exons encoding the C-terminus of BRCA1 in the mam-
mary gland of mice results in basal-like cancer [47]. Thus,
investigating the BRCA1 pathway could be an important
approach for the treatment of basal-like cancer.
BRCA1 acts as a hub protein that coordinates a diverse
range of cellular pathways to maintain genomic stability
[48]. Figure 1 shows some representative functions of
BRCA1. Many proteins whose mutation is implicated inPage 2 of 8
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[49,50] and serine/threonine-protein kinase CHK2 [51-
53], are involved in this functional network. Mutation of
the central BRCA1 gene results in ~80% penetrance of
breast cancer, and BRCA1 gene methylation or the accu-
mulated dysfunctions of other proteins whose single
mutation causes low penetrance are thought to result in
sporadic breast cancer [48,54]. BRCA1 is a component of
several different super-complexes, and, importantly,
BRCA1 partners with BARD1 to form a RING heterodimer
ubiquitin ligase [55,56] in most of these complexes [57].
This suggests that the BRCA1-BARD1 complex directs the
ubiquitylation of distinct substrates within each complex.
BRCA1-BARD1 catalyzes the formation of unconven-
tional polyubiquitin chains that include Lys6-linked
chains [58-60] or catalyzes the monoubiquitylation of
some substrates [61-64]. The putative substrates of BRCA1
in each complex are shown in Figure 1. Histones [61,62],
γ-tubulin [63] and ESR1 [64] are monoubiquitylated,
whereas NPM1 [65], RPB1 [66,67], RBBP8 (CtIP) [68],
RPAB3 (RPB8) [69], PRGR [70] and T2EA/T2EB (also
known as general transcription factor IIE or TFIIE) [71] are
polyubiquitylated and/or multiubiquitylated. Phosphor-
ylated RPB1 and PRGR are ubiquitylated and degraded in
vivo in the presence of BRCA1 [66,70]. However, there is
presently no direct evidence supporting the notion that
BRCA1-mediated ubiquitylation signals degradation. For
the other polyubiquitylated substrates NPM1 [72], RBBP8
[68], RPAB3 [69] and T2EA/T2EB [71], as well as for
BRCA1 autoubiquitylation [59], it has been proposed that
the ubiquitylation is not a signal for degradation.
Although the biochemical mechanism regarding how the
ubiquitin modifications affect intermolecular functions
remains to be clarified, some biological consequences of
the modifications have been reported. RBBP8 ubiquityla-
tion depends on the phosphorylation-mediated interac-
tion between RBBP8 and BRCA1 BRCT domains (a
phosphoserine/threonine binding motif), and ubiquit-
ylated RBBP8 associates with chromatin after DNA dam-
age to participate in G2/M checkpoint control [68].
RPAB3 is polyubiquitylated by BRCA1 after UV irradia-
tion, and HeLa cells expressing a ubiquitin-resistant form
of RPAB3 exhibit UV hypersensitivity [69]. BRCA1-medi-
ated ubiquitylation of the T2EA subunit of T2EA/T2EB
blocks the initiation of mRNA synthesis by preventing the
association between the pre-initiation complex and both
TFIIE and the general transcription factor IIH (TFIIH)
[71].
Disease models, knockouts and assays
Basal-like cancer most closely resembles features of hered-
itary breast cancer associated with BRCA1 mutation. It
also displays frequent mutations in the TP53 gene (encod-
ing cellular tumor antigen P53). Based on this correlation,
conditional mouse mutants with somatic deletion of
Brca1 and Tp53 in mammary epithelium have been gener-
ated. Female mice of this strain show a high incidence of
mammary tumors. Furthermore, the phenotype of these
tumors mimics many aspects of human basal-like breast
cancer [73]. More specifically, conditional mouse mutants
with a deletion of the C-terminus of Brca1 and also heter-
ozygous for a Tp53 mutation have also been generated.
These show a high incidence of breast tumors that are sim-
ilar to human basal-like cancer. [47] These mouse models
could well prove useful for the study of basal-like cancer
treatments.
It has recently been established that chimeric proteins
containing the tyrosine kinase and RING domain of CBL
and substituted Src-homology 2 domains from GRB2,
from the P85 regulatory subunits of phosphoinositide 3-
kinase (PI3K) or from SRC were capable of mediating
ubiquitin-dependent proteolysis of ERBB2 (HER2) [74].
Although no physiological E3 ligases for the estrogen
receptor (ESR1) and ERBB2 ubiquitylation have yet been
identified, this model could prove useful for understand-
ing ERBB2-positive cancer. Despite the fact that there are
no mouse models of ERBB2 and ESR1 function in breast
Functional network of BRCA1 and its interacting proteins that maintains genomic stabilityigure 1
Functional network of BRCA1 and its interacting 
proteins that maintains genomic stability. Mauve: puta-
tive substrates for the BRCA1-BARD1 E3 ligase. Aqua: pro-
teins encoded by genes that cause familial breast cancer or 
increase the risk of getting breast cancer. Please note that 
Swiss-Prot entry name synonyms have been used in figure – 
common synonyms are given in brackets: CHK2 (Chk2); 
CHK1 (Chk1); RBBP8 (CtIP); TOPB1 (TopBP1); FANCJ 
(BACH1/BRIP1); MRE11 (Mre11); RAD50 (Rad50); NBN 
(Nbs1); RPB1 (Pol II [RPB1]); RPAB3 (RPB8); CSTF1 
(CstF50); P53 (p53); ZN350 (ZBRK1); ESR1 (ER-α); PRGR 
(PR); STK6 (Aurora A); NPM (NPM1/B23); BRCA2 
(FANCD1); RAD51 (Rad51); PALB2 (FANCN); SMCA4 
(BRG1).Page 3 of 8
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erated for dissecting the roles of these two proteins.
Disease targets and ligands
The UPS and proteasome inhibitors
The first proteasome inhibitor that has come into clinical
practice is bortezomib (Velcade, PS-341, Millennium)
[75]. Approximately a third of relapsed, refractory multi-
ple myeloma patients show a significant response to bort-
ezomib [76], and the US FDA approved bortezomib for
use as a therapy for multiple myeloma in 2003. Borte-
zomib inhibits proteasome function in a slowly reversible
manner by means of an interaction between boronic acid
at the C-terminus of bortezomib and an active threonine
in the chymotryptic catalytic site of the 20S proteasome
[77]. The mechanisms underlying the therapeutic effect of
bortezomib in multiple myeloma have been investigated
intensively. Inhibition of the transcription factor NFκB by
blocking the degradation of its inhibitory partner IκB is
one such putative model. However, recent studies suggest
that multiple factors might contribute to the efficacy of
the drug [78]. An interesting recent study showed that
inhibition of the 26S proteasome by MG132 causes a
depletion of available nuclear ubiquitin because of the
accumulation of nondegraded polyubiquitylated proteins
in the cytosol. The depletion of free nuclear ubiquitin
resulted in a loss of monoubiquitylated histones, and
consequently this might have impaired many nuclear reg-
ulatory systems, including the DNA-damage responses
[79,80].
Clinical trials of bortezomib in many hematologic (e.g. a
phase II trial on cutaneous T-cell lymphoma by Jonsson
Comprehensive Cancer Center, NCT00182637) and non-
hematologic malignancies (e.g. phase II trials on
advanced bronchiolo-aveolar carcinoma [BAC] or adeno-
carcinoma by the California Cancer Consortium,
NCT00118144, and on pleural mesothelioma by the Irish
Clinical Oncology Research Group, NCT00513877) are
ongoing. Thus far, bortezomib has failed to show a signif-
icant clinical effect on breast cancer. Although bortezomib
was well tolerated, no responses were observed in 12
patients with aggressive metastatic breast cancers, with
extremely poor prognoses, when used as a single agent
[81]. However, the effect of combination therapy and the
therapeutic effect for selected patients, such as those with
tumors expressing a particular hormone receptor, ERBB2
(HER2) status or those in earlier stages of breast cancer,
remain to be determined.
There are increasing numbers of small molecules that tar-
get the UPS. The UPS Patent Portfolio table and UPS
Drugs & Biologicals table on the Targeted Proteins database
show the patents and drugs in development or on the
market (and the associated organizations and companies)
designed to inhibit the UPS that might be useful in breast
cancer therapy. An orally active proteasome inhibitor
salinosporamide A (NPI0052, Nereus), a natural product
derived from a marine actinomycete, resembles lactacys-
tin and irreversibly targets the proteasome [82,83,72].
Epoxomicin and eponemicin are epoxyketone-containing
natural products that exhibit antitumor activity [84,85].
Epoxomicin, currently the most specific proteasome
inhibitor, reacts irreversibly with the chymotrypsin-like
site, whereas the less-potent epoxyketone eponemicin
reacts with both the caspase-like and chymotrypsin-like
sites of the proteasome [86-88]. PR171 (carfilzomib, Pro-
teolix), a synthetic derivative of epoxomicin, has been
shown recently to have antiproliferative and proapoptotic
effects on primary human acute myeloid leukemia cells
[89].
Estrogen receptors and the UPS
Many anti-breast cancer drugs are involved in degradation
of the estrogen receptor (ESR1) [90]. The pure antagonist
fulvestrant (ICI 182780, AstraZeneca) and RU58668 pro-
mote degradation of ESR1, whereas 4-hydroxy-tamoxifen
does not [91]. Fulvestrant removes ESR1 from cyclic
recruitment to its target promoters by direct targeting of
ESR1 to the proteasome without associated transcription
[11]. NCOA3 (AIB1) also induces agonist-induced, but
not antagonist-induced, degradation of ESR1. Therefore,
the suppression of NCOA3 that results in inhibition of
estrogen-induced degradation of ESR1, but not degrada-
tion induced by fulvestrant or GW5638 [17], could have
additional clinical effects for ESR1-positive breast cancer.
Other compounds that induce degradation of ESR1
include 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a
ligand of the aryl hydrocarbon receptor (AHR) [92], and
PPARG agonists ciglitazone and 15-deoxy-delta 12,14-
prostaglandin J2 [93].
Although these existing drugs have not been designed to
modify the UPS, it is possible that they function primarily
through UPS modulation. In this regard, revealing the
precise mechanisms of degradation of ESR1 with respect
to the UPS might further improve the effectiveness of such
compounds for the treatment of breast cancer. Com-
pounds that affect the interactions of E3 ligases, coactiva-
tors and proteasome subunits in ESR1-regulated
complexes on promoters could work as anti-breast cancer
agents.
ERBB2, EGFR and the UPS
As mentioned previously, ligand-independent degrada-
tion of ERBB2 is mediated by STUB1 (CHIP) in collabora-
tion with Hsp70 and Hsp90 [33-36]. Therefore,
acceleration of this pathway might have additive antican-
cer activity when introduced with trastuzumab. The
potent anticancer agent geldanamycin, a benzoquinonePage 4 of 8
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[33,34]. In addition, the STUB1-dependent degradation
pathway of ERBB2 can be stimulated by tyrosine kinase
inhibitors such as CI1033 (Pfizer) [35]. CI1033 and
geldanamycin additively inhibit tumor cell growth.
Thus, downregulation of ERBB2 by means of acceleration
of the UPS is of crucial importance to breast cancer treat-
ment. Interestingly, however, the proteasome inhibitor
bortezomib has an additive or synergistic effect with tras-
tuzumab in the induction of apoptosis in ERBB2-positive
breast cancer cell lines [94]. It is likely that inhibition of
other UPS pathways contributes to this effect. Alterna-
tively, it could be caused by a depletion of available
nuclear ubiquitin due to the accumulation of nonde-
graded polyubiquitinated proteins, as mentioned previ-
ously [79,80].
Targets downstream of ERBB2 could also be affected by
the UPS. BIRC5 (also known as survivin), an anti-apop-
totic protein, is expressed only in tumors. Expression of
BIRC5 is associated with a poor prognosis in a variety of
malignancies, including breast cancer [95,96]. Recent
studies revealed that BIRC5 is regulated by ERBB2 and
ERBB3 but not by EGFR [97]. Interrupting the ERBB2-
ERBB3 heterodimer using lapatinib (GW572016, Glaxo-
SmithKline), a potent small-molecule inhibitor of EGFR
and ERBB2 tyrosine kinases, leads to proteasomal degra-
dation of BIRC5 and induces apoptosis both in breast can-
cer cell lines overexpressing ERBB2 and in primary tumors
[97]. Understanding the mechanisms that protect ERBB2-
overexpressing cancer cells from apoptosis might result in
new targets for therapeutic intervention.
New frontiers in drug discovery
The therapeutic effect of proteasome inhibitors on breast
cancer remains to be determined but is greatly antici-
pated. Additionally, interest is focused on the discovery of
other potent anticancer drugs that affect substrate ubiquit-
ylation by E3 ligases as well as their deubiquitylation cat-
alyzed by DUB enzymes. Because inhibition of the
proteasome, whose activity is crucial for all cell types,
imparts such a specific clinical effect, inhibiting the cata-
lytic site of E3 ligases that regulate a broad range of cellu-
lar processes, for example the RBX1 (ROC1) RING finger
subunit of Cullin-based E3 complexes [98,99], could be
equally valuable. Alternatively, E3 ligases found to be
oncogenes or tumor suppressor genes that regulate more
restricted pathways could be promising targets for small-
molecule inhibitors and activators, respectively, with
fewer side effects [100]. The following sections describe
such specific pathways that link directly to the breast can-
cer clinic.
Estrogen receptors and the UPS
Progress in hormone therapy, including aromatase inhib-
itors and the gonadotrophin-releasing hormone agonist
goserelin, has been a major contribution to the recent
improvements in breast cancer prognosis. As there already
exist several effective hormone therapy agents, it might be
conjectured that discovering additional drugs for the same
pathway is not necessary. However, approximately half of
hormone receptor-positive breast cancers do not respond
sufficiently to the current hormone therapies [101], and
therefore alternative drugs free from cross-tolerance are
needed. Compounds targeting the UPS in hormone recep-
tor signaling could be one such alternative.
ERBB2, EGFR and UPS
Trastuzumab prolongs the survival of patients with meta-
static ERBB2 (HER2)-positive breast cancer and leads to
dramatic improvements in prognosis when used in adju-
vant therapy [102]. Indeed, trastuzumab has switched
ERBB2-positive breast cancer from being a subset with the
worst prognosis to one that is curable with existing ther-
apy [102]. However, even in a subset of patients with
highly ERBB2-positive tumors, the response rate to trastu-
zumab is still limited, and alternative compounds that tar-
get the ERBB2 pathway could have additive or synergistic
roles. The UPS is definitely one such candidate. In addi-
tion to ERBB2, EGFR is overexpressed in basal-like breast
cancer and is a possible target for new anti-breast cancer
reagents.
BRCA1 and basal-like cancer
Although the significance of the E3 activity of BRCA1 in
the BRCA1 functional network (Figure 1) is only partially
understood, it is obvious that its activity is crucial in the
prevention of a certain subset of breast cancers [56,103-
105]. In terms of the potential for targeting this activity for
breast cancer therapy, tumor suppressors such as BRCA1
are not ideal targets for therapy because small molecule
activators can be more difficult to produce than small
molecule inhibitors. This is absolutely true for the treat-
ment of breast cancer caused by BRCA1 gene mutations.
However, if the breast cancer results from other factors
that cause downregulation of BRCA1 – for instance, in the
case of sporadic basal-like breast cancer – small molecules
that activate BRCA1 E3 activity could be successful.
List of abbreviations used
DUB: deubiquitylation enzyme; GFR: growth factor recep-
tor; PI3K: phosphoinositide 3-kinase; UPS: ubiquitin pro-
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